Embolus permanent protector stent-filter
Worldwide, stroke is the number three cause of death and the number one cause of adult disability. More women die of stroke than breast cancer. Today, there is no viable treatment for stroke. There are two kinds of strokes, ischemic which involves a clot (85% of strokes), and hemorrhagic which involves bleeding (15%). Of those who suffer an ischemic stroke, 94% in the US and 99% in the European Union/India will not receive the current treatment in time. Treatment must be administered within a 3.0 to 4.5 hour window from occurrence in order to prevent death or long-term care. Of those having an ischemic stroke, eight percent (8%) die in the first month, 25% in the first year and 50% are relegated to long-term care.
Every minute, 5 people suffer from a stroke which means 1 person every 12 seconds. In Europe 9.6 millions of individuals are affected by this event and killing 5.7 million annually worldwide. The cost of stroke in the US is about $65 billion and $35 billion in Europe.
The high cost and social effects of this events show that there is a need of a reinforced prophylactic action. Due to the variable outcomes of the current prophylactic treatment, the proposal in this project, is creating a new PERMANENT PREVENTIVE DEVICE. The main action of this new device is to prevent migration of the emboli to the cerebral vessels network where they may induce irreversible and everlasting effects to the patients, their families and to the society.
Companies: Frid Mind Technologies – FMT-, Bio.be, ANSYS
Universities: UMons, UNamur, Université Libre de Bruxelles
Noureddine Frid: email@example.com